The Link Between Apalutamide and QOL in Non-Metastatic CRPC

New research inLancet Oncology confirms previous studies in this population on the addition of  apalutamide to androgen deprivation therapy.

Source: CancerNetwork - October 10, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news